Advertisement

Topics

One in 10 in Rheumatic Pain Switch Back From a Biosimilar

12:49 EDT 22 Jun 2017 | Medscape

As more and more patients with rheumatic disease switch from a biologic to a biosimilar, a new study assesses how many switch back to the originator.
Medscape Medical News

Original Article: One in 10 in Rheumatic Pain Switch Back From a Biosimilar

NEXT ARTICLE

More From BioPortfolio on "One in 10 in Rheumatic Pain Switch Back From a Biosimilar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...